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Metalloproteinase-9Abstract Background: Asthma is an airway disorder associated with chronic inﬂammation that
may result in airway remodeling. Matrix metalloproteinases-9 MMP-9 recently exhibited an impor-
tant role in airway remodeling process in patients with severe asthma. The aim of the present study
was to study the effect of anti-IgE (omalizumab) on serum level of matrix metalloproteinase-9 as a
marker of remodeling in severe asthmatic patients.
Patients and methods: The present study included 50 subjects with severe uncontrolled asthma
diagnosed according to GINA guidelines. Omalizumab was prescribed for all included patients
because they were not controlled on the maximal dose of the usual standard medications including
repeated courses of systemic steroids. Pulmonary function tests, asthma control test, fraction of
exhaled nitric oxide (FENO) level, and serum MMP9 were detected for all enrolled patients.
Results: There was a signiﬁcant decrease in the number of exacerbations after 24 and 36 months
of starting omalizumab (4.3 ± 2.7 and 3.2 ± 1.2 respectively) in comparison with the baseline level
(6.2 ± 2.1) with p< 0.05. There was also a signiﬁcant increase in the ACT score in comparison
with the baseline level (11.1 ± 5.1) at 12, 24, and 36 months of starting omalizumab (13.4 ± 4.6,
15.6 ± 2.3 and 21.3 ± 3.2 respectively; p< 0.05). The baseline FEV1 % pred. was 53.4 ± 12.5.
After 24 and 36 months there was signiﬁcant improvement in the FEV1 % pred. (58.3 ± 6.2 andrculosis.
768 N. Affara et al.61.2 ± 3.4 respectively; p< 0.05). The baseline serum MMP-9 was 267.6 ± 26.8 ng/ml at the base-
line and it decreased signiﬁcantly at 12, 24, and 36 months after starting omalizumab with the p
value <0.05 (211.4 ± 19.8, 188.3 ± 31.4 and 136.15 ± 30.2 ng/ml respectively).
Conclusion: Omalizumab can reduce asthma exacerbations and improve asthma control and pul-
monary function. The reducing effect of omalizumab on metalloproteinase-9 serum level may con-
tribute to decreased airway remodeling in patients with severe asthma.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma is a chronic disease of the lower airways characterized
by airway inﬂammation, reversible airﬂow limitation, and
bronchial hyperresponsiveness [1]. Deaths from asthma con-
tinue to occur in spite of our increased understanding of the
pathophysiology of asthma, the availability of more effective
medications for the control of airway inﬂammation and
improved asthma education [2].
Persistent airway inﬂammation and irreversible structural
changes of the bronchial wall, deﬁned as airway remodeling
are thought to play a prominent role in severe asthma [3–5].
These alterations include sustained tissue eosinophilia, epithe-
lial damage, increased subepithelial basement membrane thick-
ness, subepithelial ﬁbrosis, as well as mucous gland and airway
smooth muscle hypertrophy and/or hyperplasia [3–6]. The
basement membrane is a thin layer of a specialized extracellu-
lar matrix (ECM) beneath the bronchial epithelium, which is
composed of a mixture of collagens, elastin, proteoglycans,
laminin, and ﬁbronectin. It provides structural support and
spatial orientation to overlying cells and also regulates macro-
molecule and cell trafﬁc [7]. Matrix metalloproteinases
(MMPs) are enzymes playing central roles in the turnover of
ECM components as well as tissue degradation, repair mecha-
nisms, and cell migration. Matrix metalloproteinase-9 (MMP-
9) is a 92-kDa metalloproteinase also known as gelatinase B. It
belongs to a group of gelatinases that has received special
interest because of their ability to degrade elastin and also type
IV collagen [8]. Although many intrinsic lung cells can be stim-
ulated to produce MMP-9, inﬂammatory cells are thought to
be the primary source of MMP-9 in disease [9].
Increased immunoglobulin-E (IgE) is a major pathology of
allergic asthma which stimulates chronic inﬂammation and air-
way wall thickening leading to narrowing of the airway lumen
[10,11]. Regarding the mechanism it is unclear if the stimulat-
ing effect of IgE on airway wall remodeling is direct through
the corresponding receptors or occurs indirectly by increasing
inﬂammatory mediator release from immune reactive cells or
tissue forming cells [10,11]. Omalizumab, a humanized recom-
binant murine monoclonal anti-IgE antibody, was designed to
treat patients with allergic asthma by reducing the circulating
pool of IgE able to bind to high-afﬁnity IgE receptor [12]. In
this respect, omalizumab treatment is successful as it markedly
reduces free IgE [13]. The efﬁcacy and safety proﬁle of add-on
omalizumab have been demonstrated [14]. In a 28-week, ran-
domized, placebo-controlled trial in the European Union
(INNOVATE study), omalizumab signiﬁcantly reduced oral
corticosteroid use, exacerbations and total emergency visit
rates, and signiﬁcantly improved lung function, asthma symp-
toms and quality of life [15]. The aim of the present study wasto study the effect of anti-IgE (omalizumab) on serum level of
matrix metalloproteinase-9 as a marker of remodeling in severe
asthmatic patients.
Patients and methods
The present study was conducted at Kuwait Allergy Center,
Ministry of health, State of Kuwait in the period between
June 2010 and June 2014. Written consent was taken from
all subjects included in the study before enrollment. The study
included 50 patients with severe uncontrolled asthma on usual
medications for bronchial asthma diagnosed according to
GINA guidelines [16]. All selected patients were followed up
for 3 years on monthly or twice monthly basis according to
the dose of omalizumab, which was given according to body
weight and total serum level of IgE.
Inclusion criteria:
 Bronchial asthma patient not controlled on the maximal
dose of the usual standard medication including repeated
courses of systemic steroids.
 Repeated exacerbation of symptoms and repeated emer-
gency room visits.
 Hospital admission because of asthma exacerbation for at
least 2 times in the last year.
 Positive skin prick test to the common allergen.
 Total IgE level between 30 and 700 IU/L [17].
Exclusion criteria:
 The presence of co-morbid conditions like cardiac and col-
lagen diseases or morbid obesity.
 Negative skin prick test.
 Total serum level of IgE below 30 or above 700 IU/L.
 No improvement after 6 months of therapy.
 Noncompliant patient.
All enrolled patients subjected to the followings:
 Thorough history taking, general and local chest examina-
tion and routine laboratory investigations.
 Plain chest X-ray, CT chest, and echocardiography.
 Asthma Control Test (ACT) was measured at the baseline
and then at 12, 24 and 36 months after starting omalizumab
[18].
 Pulmonary function tests (PFTs) were measured at the
baseline and then at 12, 24 and 36 months after starting
omalizumab. PFTs were made using Jaeger Masterscreen
PFT system (CareFusion, Germany) and according to
American Thoracic Society recommendations [19].
Table 1 Demographic and baseline asthma data of the
studied group.
Age in years 34.4 ± 8.3
Male to female ratio 20:30
Duration of asthma in years 18.3 ± 5.6
FEV 1% pred. 53.4 ± 12.5
ACT score 11.1 ± 5.1
FENO in ppb 81.2 ± 13.2
Serum MMP-9 in ng/ml 267.6 ± 26.8
Total serum IgE in IU/L 582.3 ± 145.7
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Pricks, Stallergenes Laboratories, France) was performed
on the forearm with a sterile needle pricked through a drop
of the extract. Positive histamine and negative diluent con-
trols were used. Reactions were recorded on the basis of the
largest diameter (in millimeters) of the wheal and ﬂare at
15 min. A wheal of 3 mm greater than the negative control
was considered positive [20].
 Fraction of exhaled nitric oxide (FENO) level was mea-
sured at the baseline and then at 12, 24 and 36 months after
starting omalizumab. Patients underwent measurement of
FENO using Niox Mino analyzer (Aerocrine AG,
Solna, Sweden) at a mouth ﬂow rate of 50 ml/s over 10 s
and a pressure of 10 cm H2O according to the guideline rec-
ommendations [21].
 Serum total and speciﬁc anti-IgE.
 Serum Matrix Metalloproteinase-9 (MMP-9) level was
measured at the baseline and then at 12, 24 and 36 months
after starting omalizumab. Serum MMP-9 was measured
using quantitative sandwich immunoassay (ELISA), sup-
plied by Oncogene Research Products; 10,394 Paciﬁc court
CA92121.
Statistical analysis
All statistical analyses were conducted using the software
package SPSS 20.0 for Windows (SPSS Inc., Chicago, IL,
USA). Data are presented as mean ± SD, Dependent t test
was used to compare data before and after using anti-IgE
treatment. Pearson’s correlation coefﬁcient was used to deter-
mine signiﬁcant correlations between the different variables.
The signiﬁcance level was set at p< 0.05.
Results
The present study included 50 patients (30 females and 20
males) with severe bronchial asthma, with the mean age of
34.4 ± 8.3 years, the duration of asthma was 18.3 ± 5.6 years,
the baseline FEV1 was 53.4 ± 12.5 % predicted, the baseline
ACT was 11.1 ± 5.1, the baseline FENO was 81.2 ±
13.2 ppb, the baseline serum MMP-9 was 267.6 ± 26.8 ng/ml,
and the baseline total serum IgE was 582.3 ± 145.7 IU/L,
(Table 1).
After the initial assessment, patients were given anti-IgE
(omalizumab) on monthly or twice monthly basis and were fol-
lowed for 3 years. Table 2 demonstrates the asthma data of the
studied group at the baseline and after 12, 24, and 36 monthsof starting omalizumab. From the table the baseline number of
exacerbation of asthma in the studied group was
6.2 ± 2.1/year, after 12 months it decreased to 5.9 ± 2.5 with-
out signiﬁcant difference from the baseline but there was a sig-
niﬁcant decrease in the number of exacerbations after 24 and
36 months of starting omalizumab (4.3 ± 2.7 and 3.2 ± 1.2
respectively) with p-value <0.05. There was also a signiﬁcant
increase in the ACT score in comparison with the baseline level
(11.1 ± 5.1) at 12, 24, and 36 months of starting omalizumab
(13.4 ± 4.6, 15.6 ± 2.3 and 21.3 ± 3.2 respectively with P-
value <0.05) demonstrating improvement in the quality of life
of the patients. The baseline FEV1 % pred. was 53.4 ± 12.5,
after 12 months of starting omalizumab there was no signiﬁ-
cant difference (54.2 ± 8.6 with p-value > 0.05) but there were
signiﬁcant improvements in the FEV1 % pred. after 24 and
36 months (58.3 ± 6.2 and 61.2 ± 3.4 respectively) with p-
value <0.05. The baseline FENO was 81.2 ± 13.2 ppb and
decreased signiﬁcantly at 12, 24, and 36 months after starting
omalizumab with p-value <0.05 (72.5 ± 8.4, 54.9 ± 12.8
and 38.9 ± 14.7 ppb respectively). The baseline serum MMP-
9 was 267.6 ± 26.8 ng/ml at the baseline and decreased signif-
icantly at 12, 24, and 36 months after starting omalizumab
therapy with the p-value <0.05 (211.4 ± 19.8, 188.3 ± 31.4
and 136.15 ± 30.2 ng/ml respectively).
On doing correlation study there was a signiﬁcant positive
correlation between the decrease in level of serum MMP-9
and decrease in FENO over the period of the study (r-value
1.88, p< 0.05) (Fig. 1) and there was a signiﬁcant negative
correlation between the decrease in level of serum MMP-9
and the improvement in the FEV1 % pred. (r-value 1.65,
p< 0.05) (Fig. 2) and asthma control test (Fig. 3) with
r-value 1.23, p< 0.05.Discussion
Asthma is a chronic inﬂammatory airway disorder involving
multiple inﬂammatory cells and mediators. Pathological repair
of chronic inﬂammation may result in airway remodeling,
which is implicated in the accelerated decline in lung function
observed in adult asthma patients over time [22]. MMP-9 is
one of the matrix metalloproteinase family recently considered
to play an important role in airway remodeling in chronic air-
way diseases, including asthma [23]. The presence of serum
immunoglobulin-E (IgE) antibodies has a central role in the
induction and maintenance of chronic allergic airway inﬂam-
mation in severe asthmatic patients that appear to be necessary
for airway remodeling to occur. Accordingly, anti-IgE thera-
pies may have the role in preventing the remodeling process
in these patients [24]. The aim of the present study was to study
the effect of anti-IgE (omalizumab) on serum level of matrix
metalloproteinase-9 as a marker of remodeling in severe asth-
matic patients.
Our study showed that omalizumab treatment signiﬁcantly
decreased asthma exacerbations and improved ACT scores
and FEV1 when compared with the baseline value. Its use also
found to decrease FeNO levels. All these results can reﬂect the
efﬁcacy of omalizumab in reducing the airway inﬂammation.
Soler et al. [25] showed that omalizumab signiﬁcantly reduced
the level of asthma exacerbations. They found that the omal-
izumab group had 58% fewer exacerbations per patient when
compared to the placebo group. Signiﬁcant reductions of
Table 2 Asthma data in the studied group at the baseline and after 12, 24, 36 months of starting omalizumab.
Variable Baseline At 12 months At 24 months At 36 months
No. of exacerbations/year 6.2 ± 2.1 5.9 ± 2.5 4.3 ± 2.7# 3.2 ± 1.2#
ACT score 11.1 ± 5.1 13.4 ± 4.6# 15.6 ± 2.3# 21.3 ± 3.2#
FEV1 % pred. 53.4 ± 12.5 54.2 ± 8.6 58.3 ± 6.2
# 61.2 ± 3.4#
FENO in ppb 81.2 ± 13.2 72.5 ± 8.4# 54.9 ± 12.8# 38.9 ± 14.7#
Serum MMP-9 (ng/ml) 267.6 ± 26.8 211.4 ± 19.8# 188.3 ± 31.4# 136.1 ± 30.2#
All values expressed as mean ± standard deviation.
# p< 0.05 when compared with baseline value.
Figure 1 Line graph representing serum levels of MMP-9 and FENO.
Figure 2 Line graph representing serum levels of MMP-9 and FEV1 (% pred.).
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reported in an analysis of 135 patients with moderate and sev-
ere allergic asthma treated with omalizumab who were at high
risk of serious asthma-related morbidity and mortality. When
omalizumab was added to baseline ICS treatment, omal-
izumab halved the incidence and frequency of exacerbations
in this high-risk population [26]. Tajiri et al. [27] treated 26
patients with severe refractory asthma using omalizumab for
48 weeks. They found signiﬁcant improvement in asthmacontrol questionnaire, FENO levels and rates of asthma exac-
erbations that required systemic corticosteroids. The efﬁcacy
of omalizumab in the improvement of pulmonary function
has been described also in other studies. Hoshino and
Ohtawa study [28] demonstrated that treatment with omal-
izumab resulted in signiﬁcant increases versus before in
FEV1 % predicted. However, no signiﬁcant differences were
observed in the subjects undergoing conventional treatment
without omalizumab.
Figure 3 Line graph representing serum levels of MMP-9 and ACT.
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MMP-9 in airway remodeling process in patients with severe
asthma. MMP-9 can increase extracellular matrix degradation
in asthma associated with structural changes in the cartilage in
airways of 1–5 mm in diameter, which may be indicative of a
more extensive destructive process in the airways [29]. In the
current study, we demonstrated that the baseline serum
MMP-9 decreased signiﬁcantly at 12, 24, and 36 months after
starting the anti-IgE therapy. The results of our study suggest
that omalizumab by decreasing MMP-9 may play a role in the
airway remodeling in patients with severe asthma. Cho et al.
[30] demonstrated that allergen-induced airway remodeling is
associated with expression of MMP-9 in the remodeled airway
in airway epithelium, as well as in peribronchial cells and the
extracellular matrix. Grzela et al. [31] stated that MMP-9
hyperactivity in asthma may be closely related to high IgE
serum levels. They further suggest that inhaled steroids may
be ineffective to prevent asthma-associated airway remodeling.
Therefore, possibly the MMP-9 inhibition may be considered
as a method of pharmacological prevention against respiratory
tract remodeling in asthma. Anti-IgE therapy acts by reducing
serum-free IgE, thereby reducing the amount of IgE binding to
mast cells, basophils, and eosinophils [24]. This prevents the
degranulation of allergen-bound mast cells, which would
otherwise result in the release of pro-inﬂammatory cytokines
(including IL-4, IL-13, and IL-5) associated with airway
remodeling. Huang et al. [32] evaluated the effects of omal-
izumab on allergen- and growth factor-stimulated proinﬂam-
matory cytokine and nitric oxide production in human
bronchial epithelial cells. Anti-IgE therapy has been shown
to prevent the production of pro-inﬂammatory cytokines and
growth factors and as a result, the authors of that study con-
cluded that it probably contributes to decreased airway remod-
eling in patients with asthma. Riccio et al. [33] investigated the
effect of long-term anti-IgE on the thickening of the reticular
basement membrane (RBM) and eosinophil inﬁltration in
bronchial biopsies from 11 patients with severe persistent aller-
gic asthma before and after 12 months of treatment with oma-
lizumab. The study showed that a substantial proportion of
severe asthmatics reduced the original bronchial RBM thick-
ness and eosinophil inﬁltration after one-year treatment with
anti-IgE. An ongoing EXCELS study [34] is underway toassess the effect of anti-IgE therapy on markers of airway
remodeling and may provide additional information on the
efﬁcacy and safety of anti-IgE therapy.
Conclusion
Omalizumab can reduce asthma exacerbations and improve
asthma control and pulmonary function. The reducing effect
of omalizumab on metalloproteinase-9 serum level may con-
tribute to decreased airway remodeling in patients with severe
asthma.Conﬂict of interest
There is no conﬂict of interest.
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